PLSE PULSE BIOSCIENCES, INC.

CIK 0001625101 50 ready 8-Ks latest May 4, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 3 baseline

Ready 8-Ks 50

Latest filing May 6, 2026, 7:59 PM ET

Top materiality 0.80

Event mix other_material ×32 · leadership ×8 · earnings ×6

Sentiment 22 pos · 4 neg · 24 neu

Executive change recent →

Recent 8-K filings for PLSE

Highest-materiality recent filing

Pulse Biosciences reports 100% 6-month and 96% 12-month ablation success in nPulse study

April 27, 2026, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 9.01

Sustained 100% procedural success at 6 months (95/95 evaluable patients by holter).
Sustained 96% procedural success at 12 months (51/53 evaluable patients).

Read filing →

May 4, 2026, 7:59 PM ET other material materiality 0.75 neutral item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Pulse Biosciences Q1 net loss $18.6M; accelerates NANOPULSE-AF enrollment to early Q4 2026

Preliminary Q1 2026: cash $68.3M, net loss $18.6M, cash used in ops $14.6M.
April 27, 2026, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 9.01

Pulse Biosciences reports 100% 6-month and 96% 12-month ablation success in nPulse study

Sustained 100% procedural success at 6 months (95/95 evaluable patients by holter).
April 7, 2026, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Pulse Biosciences enrolls first 7 patients in NANOPULSE-AF pivotal trial for nPulse AFib catheter

First 7 patients treated at St. Bernards Medical Center by Devi Nair, MD.
March 17, 2026, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Pulse Biosciences realigns to accelerate AFib catheter program after strong clinical data

100% acute success at 6 months (75/75 patients); 96% durable PVI at 12 months (45/47).
March 9, 2026, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Pulse Biosciences reports 74% avg volume reduction in benign thyroid nodule ablation at 15-22 months

21 patients monitored 15-22 months; average 74% volume reduction of benign thyroid nodules with no regrowth.
March 3, 2026, 6:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

Pulse Biosciences updates investor deck with nPulse catheter development, cites 'unprecedented' EU feasibility data

Updated investor presentation posted on website includes summary financial info and product development update.
March 2, 2026, 6:59 PM ET leadership materiality 0.70 negative item 5.02 item 9.01

Pulse Biosciences CCO Kevin P. Danahy resigns effective immediately

Kevin P. Danahy, Chief Commercial Officer, resigned effective February 27, 2026.
February 19, 2026, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Pulse Biosciences Q4 rev $264K, GAAP net loss $17.4M; FDA clears pivotal AF study

Q4 2025 revenue $264K (vs $86K Q3), full-year revenue $350K. GAAP net loss Q4 $17.4M, full year $72.8M (vs $53.6M prior year).
February 6, 2026, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Pulse Biosciences reports 96% procedural success at 12 months for nPulse AF ablation study

100% procedural success at 6 months (75/75); 96% at 12 months (45/47) in first-in-human feasibility study.
December 18, 2025, 6:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

Pulse Biosciences receives FDA IDE approval to initiate NANOPULSE-AF clinical study for paroxysmal atrial fibrillation

FDA approved IDE for Pulse Biosciences' nPulse Cardiac Catheter System to treat paroxysmal atrial fibrillation in NANOPULSE-AF study.
November 5, 2025, 6:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01

Pulse Biosciences Q3 2025 revenue $86k, GAAP net loss ($19.4M), cash $95.2M

Revenue of $86k from limited market release of nPulse Vybrance system.
October 24, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Pulse Biosciences enrolls first patient in NANOCLAMP AF study for AF treatment using nPulse system

First procedure completed at St. Helena Hospital in St. Helena, CA with nPulse Cardiac Surgical System using nanosecond PFA.
October 10, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Pulse Biosciences reports 94% PVI success at 3 months in nPulse cardiac study

All (100%) posterior box isolations acutely successful in high-dose cohort; 94% PVI success per vein at ~3 months.
September 8, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Pulse Biosciences receives FDA IDE approval for nsPFA Cardiac Surgery Study NANOCLAMP AF

FDA granted IDE approval for the NANOCLAMP AF study of nsPFA Cardiac Surgical System to treat atrial fibrillation.
September 2, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Pulse Biosciences enrolls first patients in PRECISE-BTN study for benign thyroid nodules

First successful procedures using nsPFA Percutaneous Electrode System for benign thyroid nodules (BTNs).
August 26, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Pulse Biosciences publishes FIH data for nsPFA thyroid nodule treatment in Thyroid journal

Single-arm feasibility study by Prof. Spiezia at Ospedale del Mare, Naples, Italy; three cohorts.
August 12, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Pulse Biosciences Q2 net loss widens to $19.2M; advances nsPFA clinical programs with FDA IDE submissions

GAAP net loss ($19.2M) vs ($11.4M) YoY; non-GAAP net loss ($13.7M) vs ($9.0M).
March 28, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Pulse Biosciences Q4 GAAP net loss widens to $19.4M; cash boosted to $118M on warrant exercises

GAAP net loss of $19.4M in Q4 2024 vs $11.9M a year ago; full-year loss $53.6M vs $42.2M.
February 4, 2025, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Pulse Biosciences appoints Jon Skinner as CFO effective Feb 3, 2025

Jon Skinner appointed CFO effective Feb 3, 2025; previously VP at Copeland and Imperative Care.
January 23, 2025, 6:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Pulse Biosciences reports 92.4% PVI success at ~3 months in nsPFA catheter feasibility study

77 patients treated; first 30 evaluated at ~3 months remap with 92.4% PVI success (109/118 veins).
January 13, 2025, 6:59 PM ET leadership materiality 0.80 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Pulse Biosciences appoints Paul LaViolette as CEO; grants 1.5M stock options with revenue/market cap milestones

Paul LaViolette, former Co-Chairman, becomes CEO and President effective Jan 9, 2025.
December 6, 2024, 6:59 PM ET leadership materiality 0.65 neutral item 5.02

Pulse Biosciences CEO Barrett resigns; Danahy, Uecker named interim executives

CEO Burke T. Barrett resigns effective Dec 6, 2024; also leaves board Dec 2, 2024.
November 26, 2024, 6:59 PM ET other material materiality 0.60 positive item 7.01

Controlling stockholder Robert Duggan cleared to buy up to 500k PLSE shares by Dec 10

Robert W. Duggan, controlling stockholder and Co-Chairman, authorized to purchase up to 500,000 shares of common stock through December 10, 2024.
October 30, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 8.01 item 9.01

Pulse Biosciences Q3 net loss $12.7M; appoints Dr. Kenigsberg as CMO for Electrophysiology

GAAP net loss $12.7M in Q3 2024 vs $10.6M in Q3 2023; cash $79M including $60M rights offering.
August 12, 2024, 7:59 PM ET other material materiality 0.70 positive item 2.02 item 5.02 item 9.01 ◈ executive_change ×3

Pulse Biosciences reports Q2 prelim costs $11.7M; appoints Paul LaViolette as Co-Chairman

GAAP costs and expenses $11.7M for Q2 2024; non-GAAP $9.4M; cash $26.2M as of June 30, excluding $60M rights offering closed July 2024.
August 8, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Pulse Biosciences treats first two patients in first-in-human study of nano-PFA Cardiac Surgery System for AFib

Successfully treated first two AFib patients using nano-PFA Cardiac Surgery System at St. Antonius Hospital, Netherlands.
July 15, 2024, 7:59 PM ET other material materiality 0.80 negative item 1.01 item 2.02 item 9.01

Pulse Biosciences enters $60M ATM equity facility; prelim Q2 net loss $10.7-12.7M

Up to $60M at-the-market offering via Canaccord Genuity and Needham; commission up to 3%.
July 8, 2024, 7:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

Pulse Biosciences receives FDA Breakthrough Device Designation for nsPFA Cardiac Surgery System for AF treatment

FDA Breakthrough Device Designation for CellFX nsPFA Cardiac Surgery System to treat atrial fibrillation.
July 3, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Pulse Biosciences closes $60M rights offering at $10/unit, oversubscribed 138%

Raised $60M gross from 6M units; each unit = 1 share + 2 warrants to buy 0.5 share at $11.
June 28, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Pulse Biosciences rights offering oversubscribed, raises $60M; Duggan to hold ~72%

Offering oversubscribed at 138%, receiving over $83M in subscriptions vs $60M limit.